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ABSTRACT 
Rationale: Myocardial infarction (MI) is one of the leading causes of death 
worldwide and inflammation is central to the tissue response and patient outcomes. The 
18kDa translocator protein (TSPO) has been utilized in positron emission tomography 
(PET) as an inflammatory biomarker. The aims of this study were to: 1) screen novel, 
fluorinated, TSPO radiotracers for susceptibility to the rs6971 genetic polymorphism using 
in vitro competition binding assays in human brain and heart, 2) assess whether the in 
vivo characteristics of our lead radiotracer, 18F-LW223, are suitable for clinical translation 
and 3) validate whether 18F-LW223 can detect macrophage driven inflammation in a rat 
myocardial infarction model. 
Methods: Fifty-one human brain and twenty-nine human heart tissue samples were 
screened for the rs6971 polymorphism. Competition binding assays were conducted with 
3H-PK11195 and the following ligands: PK11195, PBR28 and our novel compounds 
(AB5186 and LW223). Naive rats and mice were used for in vivo PET kinetic studies, 
radiometabolite studies and dosimetry experiments. Rats underwent permanent coronary 
artery ligation and were scanned using PET/CT with invasive input function at 7 days 
following MI. For quantification of PET signal in the hypoperfused myocardium, K1 was 
used as a surrogate marker of perfusion to correct the binding potential for impaired 
radiotracer transfer from plasma to tissue (BPTC). 
Results: LW223 binding to TSPO was not susceptible to the rs6971 genetic 
polymorphism in human brain and heart samples. In rodents, 18F-LW223 displayed a 
specific uptake consistent with TSPO expression, a slow metabolism in blood (62% of 
parent at 120 min), a high plasma free fraction of 38.5% and a suitable dosimetry profile 
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(effective dose of 20.5-24.5 μSv/MBq). 18F-LW223 BPTC was significantly higher in the MI 
cohort within the infarct territory of the anterior wall relative to the anterior wall of naive 
animals (36.9±8.8 vs. 10.0±2.4 cm3/mL/min, p≤0.001). Ex-vivo immunofluorescent 
staining for TSPO and CD68 (macrophage marker) resulted in the same pattern seen 
with in vivo BPTC analysis. 
Conclusion: 18F-LW223 is not susceptible to the rs6971 genetic polymorphism in in vitro 
assays, has favorable in vivo characteristics and is able to accurately map macrophage 
driven inflammation following MI. 
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INTRODUCTION 
Cardiovascular disease is the leading cause of morbidity and mortality worldwide 
(1). A large proportion of these fatalities is due to myocardial infarction (MI). Acute 
inflammation is a key driver of pathology determining disease perturbation following tissue 
infarction (2). Therefore, an urgent need exists for a non-invasive imaging technology to 
act as a prognostic tool and predict subsequent patient outcomes.  
The 18kDa translocator protein (TSPO) is expressed within the outer membrane 
of the mitochondria (3) where it is a key factor in controlling the transport of cholesterol 
necessary for steroid hormone synthesis. TSPO is highly expressed within inflammatory 
cells such as macrophages in the periphery (4) and microglia in the brain (5), and has 
consequently been used as a marker of inflammation in pathologies throughout the body 
(4,6–10).  
Despite TSPO being one of the most widely explored targets in the field of Positron 
Emission Tomography (PET), clinical adoption of this tissue biomarker has been globally 
hindered by radiotracers with suboptimal properties. For example, the prototypical TSPO 
ligand 11C-PK11195 (11) has relatively high non-specific binding and a short half-life (12). 
Efforts to surpass the limitations of 11C-PK11195 have been hampered primarily by the 
differential binding of second generation TSPO radiotracers now known to be caused by 
the rs6971 genetic polymorphism (13). Moreover, the use of TSPO PET radiotracers in 
the context of cardiovascular disease, in particular following MI, has faced limited 
adoption due to lack of validated paradigms for quantification of regional tissue 
inflammation in hypoperfused areas using a single technique/single scan. Previously, 
quantification of regional tissue inflammation following MI has relied on the use of TSPO 
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PET static imaging and Single Photon Emission Computed Tomography (SPECT) 
perfusion static scans for correction of the TSPO PET data (6). Consequently, there is a 
need to develop improved TSPO PET ligands and methodology to boost adoption of this 
technology for non-invasive imaging of inflammation in cardiology.   
This study aims to: 1) screen novel, fluorinated, TSPO radiotracers for 
susceptibility to the rs6971 genetic polymorphism using the gold standard in vitro 
competition binding assays in human brain and heart, 2) assess whether the in vivo 
characteristics of our lead radiotracer is suitable for clinical translation and 3) validate 
whether our novel TSPO radiotracer can detect macrophage driven inflammation in a rat 
myocardial infarction model. 
 
MATERIALS AND METHODS 
Radiotracer Preparation 
A four-step synthetic strategy was developed for the preparation of the chloride 
precursor and LW223 (Supplemental Fig.1). Initially, the starting material 3-methyl-4-
phenylquinoline-2-carboxylic acid was prepared as previously reported by us (14). This 
was converted to the (R)-sec-butylamide by coupling with (R)-sec-butylamine and using 
the coupling agent HBTU. Under standard basic conditions, the amide was subjected to 
an N-methylation. The key step then involved a radical-mediated bromination of the 3-
methyl substituent using N-bromosuccinimide and the radical initiator benzoyl peroxide. 
The resulting bromide intermediate was then converted to the chloride or LW223 using 
lithium chloride or sodium fluoride, respectively. All intermediates and final compounds 
were purified by column chromatography and characterized using a combination of NMR 
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spectroscopy  and mass spectrometry (see organic chemistry section within the 
supplemental file for details (14,15)). The two amide rotamers of LW223 were separated 
and characterized by LC-MS (Supplemental Fig.2). 
18F-LW223 was prepared as shown in Figure.1, using the GE TRACERlab® FXFN 
synthesizer. The radiotracer was purified by semi-preparative High Performance Liquid 
Chromatography using the following conditions: C18 Synergi Hydro-RP 80 Å, 150×10 
mm, 4 µm column (Phenomenex, UK), acetonitrile/water (70:30 v/v) and flow rate of 3 
mL/min. 18F-LW223 was formulated in 10% ethanol in saline. The average radioactivity 
yield was 50±4% (starting from 22±3 GBq of 18F-fluoride, n = 34) after a total synthesis 
time of 55 minutes. The identity of 18F-LW223, radiochemical purity (>99%) and molar 
activity (89±12 GBq/µmol, n = 34) were determined by High Performance Liquid 
Chromatography analysis at the end of synthesis. 
 
In Vitro Competition and Saturation Binding Assays with Human Tissue 
All studies using human tissue were conducted in accordance with the National 
Health Service Research Ethics Committee South East Scotland (NHS-RECSE, 
Edinburgh Brain and Tissue Bank, 16/ES/0084). Supplemental Table.1 contains the BNN 
reference number for all tissues utilized from the Edinburgh Brain and Tissue Bank. Fifty-
one brain (78% male, age 53.9±9.5) and twenty-nine heart (83% male, age 48.2±13.2) 
samples were obtained and screened for the rs6971 genetic polymorphism and grouped 
into HAB, MAB or LAB as previously described (13). Samples were homogenized in 10× 
w/v buffer (50 mM Tris-Base, pH 7.4, 4 ºC) before centrifugation (32,000 g, 10 min, 4 ºC). 
Tissue pellets were then resuspended in 10× w/v buffer and centrifuged again before 
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resuspending in 2 mL of buffer. Samples were assessed for protein concentration using 
the Bio-Rad protein assay (Bio-Rad, USA), aliquoted and stored at -80 ºC until use. The 
competition binding assay protocol was adjusted from a previously reported protocol (16), 
as detailed within the supplementary file. 
 
Animals and Surgical Procedures 
All experiments were authorized by the local University of Edinburgh animal 
welfare and ethical review committee and in accordance with the Home Office Animals 
(Scientific Procedures) Act 1986. Thirty-three adult male Sprague-Dawley rats (312.1± 
15.0 g), and thirteen C57Bl/6 (8 male, 5 female, 25.5± 1.5 g) were used for this study. 
The animals were housed under standard 12 h light:12 h dark conditions with food and 
water available ad libitum. On the day of the experiment, anesthesia was induced and 
maintained with 1.5–2.5% isoflurane (50/50 oxygen/nitrous oxide, 1 l/min). For imaging 
experiments, an intravenous (i.v.) line was established in the femoral vein or tail vein for 
injection of the radiotracer and the femoral artery was cannulated to allow automated 
blood sample collection, as previously described (17). In a separate set of experiments 
(radiometabolite studies), the femoral artery was cannulated for blood sampling and the 
radiotracer was administered i.v. via tail vein. Surgical cannulation of femoral vein and 
artery was performed as detailed in the supplementary file.  
Body temperature was maintained by heated scanner bed or heated mat and 
monitored by rectal thermometer. Vital signs, including heart rate and respiration rate 
were monitored continuously during the experiments. 
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For MI studies, anesthesia was induced and maintained using isoflurane (0.5-3% 
in 1.0 l/min oxygen) before buprenorphine (0.05 mg/kg, Alstoe Ltd, York, UK) was 
administered preoperatively for analgesia. Tracheal intubation was achieved under direct 
vision, and ventilation was maintained with a rodent ventilator (Harvard Apparatus Model 
683, MA, USA, tidal volume 2.5 cm3, respiratory rate 60/min). Myocardial infarction was 
induced as we have previously described (18) and further details can be found in the 
supplementary file. Animals were imaged on day 7±1 post-MI, referred to as day 7 
throughout the manuscript. 
 
In Vivo PET Imaging 
Study Design 
Thirty-two PET scans were performed with 18F-LW223 (17.8± 1.5 MBq, bolus i.v., 
mean± standard error of the mean (SEM)). Naive and MI rat scans were acquired 
immediately following i.v. bolus injection of 18F-LW223. Blocking studies were carried out 
in rats with PK11195 (1 mg/kg, i.v.) 30 min prior to receiving 18F-LW223. For displacement 
studies, rats received 18F-LW223 and were scanned continuously for 120 min, with single 
dose of PK11195 (1 mg/kg, i.v.) administered at the 60 min time-point. Dosimetry studies 
were conducted using mice and 240 min PET scans. 
 
Arterial Input Functions 
A commercially available system (Twilite2, Swisstrace, Switzerland) was used for 
the measurement of blood radioactivity as previously described (17). The whole-blood 
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arterial input function measured by the automatic blood sampler was corrected for the 
plasma-to-whole blood ratio and for metabolism in vivo. 
 
Image Acquisition and Reconstruction 
Data were acquired using a PET/CT small animal scanner (nanoPET/CT, Mediso, 
Hungary). A CT scan (semi-circular full trajectory, maximum field of view, 480 projections, 
50 kVp, 300 ms and 1:4 binning) was acquired for attenuation correction. Immediately 
following radiotracer administration, a 120 or 240 minutes emission scan was obtained 
using 3-dimentional 1:5 mode and re-binned as follows: Rat studies= 18×10 sec; 2×30 
sec; 1×60 sec; 2×2 min; 10×5 min; 6×10 min or 18×10 min, Mouse studies=4×5 min, 4×10 
min, 9×20 min. Rat PET studies were reconstructed using Mediso’s iterative Tera-Tomo 
3D reconstruction algorithm, which includes point spread correction, and the following 
settings: 4 iterations, 6 subsets, full detector model, low regularization, spike filter on, 
voxel size 0.4 mm and 400-600 keV energy window. Mouse dosimetry PET data were 
reconstructed using filtered back projection (FBP) and the following settings: voxel size 
0.4 mm and 400-600 keV energy window. All PET data were corrected for randoms, 
scatter and attenuation. 
 
Image Processing and Data Analysis 
Reconstructed scans were imported into PMOD version 3.8 (PMOD Technologies, 
Switzerland). Volumes of interest (VOIs) were manually drawn around the brain, heart 
and lung using CT images. To sample the infarct area (or equivalent area in naïve hearts) 
averaged PET images (0-120 minutes) were used to place three spherical VOIs at the 
by on October 12, 2020. For personal use only. jnm.snmjournals.org Downloaded from 
11 
 
centre of the infarct territory within the ventricular wall (1.5 mm3). Only the right lung was 
used for analysis in MI rats to avoid surgical induced trauma (left lung is deflated during 
the surgical procedure). Time-activity curves were generated and standard uptake values 
(SUVs) calculated as concentration in the VOI divided by injected dose divided by animal 
weight. Kinetic modelling was performed using the two-tissue compartment model to 
estimate the kinetic rate constants K1 to k4 and VT in different tissues. VB was not modelled 
in this study. Two-tissue modelling was selected as the preferred model based on a 
comparison of goodness and robustness of fitting versus several other models 
(Supplemental Fig.3 and Supplemental Table.2). The binding potential relative to non-
displaceable volume (BPND) was defined as k3/k4 (19). The transfer corrected BPND, 
termed BPTC, was formulated as below: 
𝐵𝑃்஼ = ௞య௞ర ÷ 𝐾ଵ  Eq. 1 
where k3=radiotracer association rate with specific binding, k4=dissociation rate constant 
of target-ligand and K1=rate constant for transfer from arterial plasma to tissues. When 
tissue blood flow is impaired, such as post-MI, K1→blood flow, as per Renkin-Crone 
equation: 
𝐾ଵ = 𝐹 × 𝐸 = 𝐹 (1 − 𝑒ି ುೄಷ )  Eq. 2 
where F=flow, E=extraction and PS=permeability. 
 
Dosimetry 
Reconstructed whole-body PET scans were imported into PMOD 3.8 and VOIs 
were drawn around organs that displayed higher radioactivity concentration than 
background, i.e. source organs. The following organs were identified as source organs; 
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brain, heart, lung, gallbladder, liver, gut, adrenals, kidneys and bladder. A whole-body 
VOI was drawn around the animal body and was used for quantification of whole-body 
remainder activity as whole-body activity minus source organs activity. At each time point, 
the measured activity of the source organs were expressed as the percent injected dose 
(%ID). The residence time τ, defined as the ratio of accumulated activity in the target 
organ (Ā) and injected activity (A0); τ=Ā/A0(20), was calculated as previously described 
(21). Calculated τ were normalized based on the factors shown in Supplemental Table.3 
(22–26) and entered into OLINDA/EXM 1.0 software to estimate organ doses and 
effective doses.  
 
Radiometabolite Blood and Tissue Processing and Analysis 
Arterial blood samples were collected at 2, 5, 10, 20, 30, 60 and 120 minutes; 
heart, lung and brain tissue samples were collected at 60 and 120 minutes post-
radiotracer injection (69.7±9.1 MBq, mean±SEM, n =17 rats). Blood and tissues were 
processed as detailed in the supplementary file.  
 
Ex Vivo Immunofluorescence Imaging 
 Naive and MI heart tissue was fixed in 10% neutral buffered formalin for 24 hours, 
wax processed and sectioned. The CD68 (a macrophage marker) and TSPO stain was 
carried out using a double tyramide signal amplification (TSA) visualization as described 
previously (27). Mouse and rabbit IgG at an equal concentration served as an isotype 
control. Full details on immunohistochemistry tissue processing protocols used can be 
found in the supplementary file.  
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 Whole tissues were imaged using an Axio Scan.Z1 slide scanner (Zeiss, 
Germany). Quantification was performed using Image J (v1.49, NIH, USA) by selecting 
regions of interest and quantifying the mean intensity for each channel of interest.  
 
General Statistical Analysis 
GraphPad Prism version 6 (GraphPad Software Inc., USA) was used for data 
fitting, statistical analysis and production of graphs. In competition binding assays and 
saturation assays, outliers within experimental triplicates were removed using a Grubbs 
test with an alpha of 0.2. Two-way ANOVA with post-hoc Sidak, Pearson correlations and 
unpaired and paired t-tests were used in this study for comparison between two groups, 
as indicated within the relevant figure legends, with a p<0.05 considered statistically 
significant. All error bars represent the standard error of the mean (SEM), unless 
otherwise indicated in the figure or table legends. 
 
RESULTS 
Binding of Our Lead Compound, LW223, To TSPO Is Not Affected By the rs6971 
Polymorphism in In Vitro Assays 
The inhibition constant (Ki) (28) of PK11195, two PK11195 analogues (AB5186 
(29) and LW223, our lead compound) and PBR28 (Fig.2.A) were investigated in this 
study. Saturation assays were used to determine the Kd of PK11195 (Supplemental 
Fig.4). 
In the human brain, PK11195 Ki was unaffected by the genetic polymorphism 
(Fig.2.B, Left), unlike PBR28 (Fig.2.B, Middle Left). AB5186 Ki was affected by the 
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genetic polymorphism (Fig.2.B, Middle Right), unlike LW223, which was unaffected 
(Fig.2.B, Right). There were no differences between HAB and LAB in PK11195 and 
LW223 binding studies (Supplemental Fig.5.A and G). Conversely, Ki values in HAB and 
LAB for PBR28 and AB5186 revealed differences between groups (Supplemental Fig.5.C 
and E). LW223 mean Ki was 0.6 nM, twice higher than PK11195.  
In the human heart, the Ki of PK11195 was independent of the genetic 
polymorphism (Fig.2.C, Left). PBR28 and AB5186 were also affected to a similar degree 
in the heart as in the brain (Fig.2.C, Middle Left and Middle Right). LW223 binding in the 
heart was unaffected by the polymorphism (Fig.2.C, Right). Ki values for all heart samples 
demonstrated no differences between HAB and LAB in PK11195 and LW223 binding 
studies (Supplemental Fig.5.B and H). In the heart, LW223 mean Ki was the same as 
PK11195 at 1.7 nM. Individually calculated Ki values for PBR28 and AB5186 revealed a 
difference between HAB and LAB (Supplemental Fig.5.D and F).  
 
 18F-LW223 Binds to TSPO In Vivo  
In mice and rats 18F-LW223 rapidly distributed to TSPO expressing tissues, 
including brain, heart and lung following administration. It was eliminated via both the 
urinary and hepatobiliary excretion routes (Fig.3.A, Left).  
Radiometabolism of 18F-LW223 in rat arterial blood was slow with approximately 
62% of the parent compound remaining at 120 min post-injection (Fig.3.A, Middle and 
Supplemental Fig.6). Less than 12.7% radiometabolites were measured in the brain, 
heart and lung at 60 and 120 min post-administration (Fig.3.A, Right and Supplemental 
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Fig.7). The measured parent free fraction in plasma (fp) was 38.5±7.0% (mean±SEM, n = 
5). 
Peak SUVs in naive rat brain, heart and lung were 0.83±0.18, 2.51±0.31 and 
3.98±0.35 g/mL, respectively. Post-peak uptake, elimination of the radiotracer was faster 
in the brain and lung compared with the heart (Supplemental Fig.8). Time activity curves 
were noisier in the sampled LV sub-region relative to whole organ VOIs (Supplemental 
Fig.8.D-F). 18F-LW223 kinetics in naive rats were blockable (Fig.3.B-C), reversible 
(Supplemental Fig.9) and could be described by the 2-tissue compartmental model 
(2TCM, Supplemental Table.4).  
In naive mice, the highest %injected dose was in the gut followed by the liver, lung, 
kidneys, heart, brain, gall bladder, urinary bladder and adrenals. Dosimetry estimates 
demonstrated that the critical organ was the lower large intestine. The whole-body 
effective dose was estimated to be 20.5 (male) and 24.5 μSv/MBq (female, Table.1).  
 
 18F-LW223 BPTC Allows for Detection of Macrophage-Driven Inflammation in the 
Hypoperfused Myocardium Following-MI 
In non-perfusion-corrected SUV heart images there was an increase in 18F-LW223 
signal globally with a lack of signal within the left ventricle (LV) anterior wall (area of the 
infarct, Fig.4.A, Left) seven days following MI. There was a significant decrease in the 
measured total volume of distribution (VT) in the LV anterior wall, i.e. infarct area, in the 
MI group (Fig.4.A, Middle). VT and SUV values at pseudo-equilibrium (SUV40-60) in naive 
and MI animals significantly correlate (Supplemental Fig. 10). However, heart VOIs on 
their own do not correlate in MI animals suggesting that VT and SUV are not equally 
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affected by tissue hypoperfusion induced by the coronary artery ligation. The K1 was also 
significantly reduced in the LV anterior wall of the MI group (Fig.4.A, Right and 
Supplemental Table.4). The measured reduction in all modelling constants was not linear, 
with k2 only reducing 1.4 fold versus 3.6 fold for K1 (Supplemental Table.4). The ratio of 
the constants k3/k4 remained unchanged between groups (Supplemental Table.4). 
Fig.4.B contains examples of parametric images of a left ventricle from the MI group, with 
the perfusion deficit caused by the ligation of the left anterior descending artery clear in 
the K1 image (Left). The BPTC parametric imaging data showed a clear signal mainly 
within the infarct (Fig.4.B, Middle). Quantification of BPTC between groups demonstrated 
a significant increase between naive and MI within the LV anterior wall (Fig.4.B, Right). 
There was no statistically significant changes in measured 18F-LW223 concentration in 
whole blood following MI (Supplemental Fig.11). 
Validation of BPTC was performed by ex-vivo analysis of naive and MI hearts and 
immunofluorescent staining of TSPO and CD68 (Fig.4.C). In the naive and MI heart, the 
vast majority of TSPO staining (green, cytoplasmic) was found in macrophages which 
were CD68 positive (red, cytoplasm and cell surface). These markers only occasionally 
co-localized to the same region of the cell (yellow) due to their sub-cellular distribution. 
Quantification of TSPO staining revealed a significant increase in the LV anterior wall of 
the MI group (Fig.4.D, Left), which was also the case for CD68 (Fig.4.D, Middle). TSPO 
within the global heart and LV anterior wall significantly correlated with CD68 (Fig.4.D, 
Right). A trend towards a small increase in TSPO and CD68 staining was observed in the 
remote myocardium (i.e. posterior left ventricle, Supplemental Fig.12). 18F-LW223 
autoradiography in these samples also demonstrated an increase in signal within the MI 
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group (one-way ANOVA, p<0.05), although it lacked the statistical power to determine 
significant regional differences in post-hoc analysis (Supplemental Fig. 13). The 
localization, and correlation, of TSPO and CD68 within the infarct in ex vivo analysis 
validates the expression pattern seen for 18F-LW223 BPTC in vivo (Fig.4.B, Right) and 
reflects macrophage-driven inflammation in the heart following-MI. 
Our simulation work using ideal noise-free conditions shows that the difference 
between truth BPND and estimated BPND is more pronounced for low K1 values 
(Supplemental Fig.14, Supplemental Tables 5 to 8). This simulates conditions of severe 
hypoperfusion, such as those observed during MI. Furthermore, data shows that in areas 
of low BPND (e.g. brain), the reduction of K1 needs to be much higher than in areas of 
expected high BPND (e.g. infarct region), in order to impact BPND measures (Supplemental 
Fig.14). 
 
18F-LW223 PET Corroborates Existence Of An Inflammatory Heart:Brain Axis in 
Rats Following-MI 
In line with previous observations in mice and humans (6), we investigated the 
existence of a TSPO heart: brain inflammation axis in rats 7 days following MI. There was 
a significant positive correlation of the 18F-LW223 signal (in vivo, Fig.5.A, Left Row and 
Fig.5.B, Top), TSPO (ex-vivo immunofluorescence, Fig.5.A, Middle Row and Fig.5.B, 
Middle) and CD68 (ex-vivo immunofluorescence, Fig.5.A, Middle Row and Fig.5.B, 
Bottom) expression between the heart and brain of naive and MI rats. Ex-vivo TSPO 
analysis revealed a significant increase following MI within the lateral ventricles of the 
brain, but no significant change in the global brain, hippocampus, thalamus or cortex 
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(Supplemental Fig.15). Examples of TSPO and CD68 cellular expression with and without 
co-localization in the brain are shown in Fig.5.A (right row). 
 
DISCUSSION 
The first aim of this study was to develop a novel TSPO ligand that was insensitive 
to the rs6971 genetic polymorphism in vitro using the gold standard human tissue 
competition binding assays and two types of tissue (brain and heart); which in this case 
was LW223. Three recently developed PET compounds have also been proposed to be 
insensitive to the human rs6971 genetic polymorphism: 18F-FEBMP (small pilot 
autoradiography study, n = 2) (30), (R)-18F-NEBIFQUINIDE (binding assessed using 
human thrombocyte membranes) (31), and (R,S)-18F-GE387 (binding assessed using 
human embryonic kidney cell lines overexpressing human TSPO wild-type and TSPO 
A147T) (32). Unfortunately, 18F-FEBMP underwent considerable metabolism when 
assessed in rats, with <10% of the original parent compound found in blood at 30 min 
post-injection (30). In vivo kinetic properties in animal models of disease and dosimetry 
estimates of both (R)-18F-NEBIFQUINIDE and (R,S)-18F-GE387 are yet to be fully 
assessed. Meanwhile, our study presents detailed in vivo kinetic modelling, target-
engagement quantification and animal disease model studies with 18F-LW223. Thus, 18F-
LW223 is the most advanced fluorinated TSPO-PET radiotracer with desirable in vivo 
characteristics and insensitivity to the rs6971 polymorphism in human tissue (as opposed 
to cell lines and blood cells), which is necessary for clinical translation, reported to date. 
Our robust translational package reported here with 18F-LW223 is further 
complemented by detailed in vivo characterization. 18F-LW223 has excellent in vivo 
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properties for imaging TSPO non-invasively. While it is not easy to compare to other 
radiotracers directly due to differences in species and experimental methods, 18F-LW223  
had a VT in the brain of 1.2-2.13 mL/cm3, which was higher than reported values for 11C-
PK11195 (0.6-0.74 mL/cm3) (33) and 18F-GE180 (0.10-0.28 mL/cm3) (34,35). This  was 
in line with other promising TSPO radiotracers such as 11C-ER176 (1.6-3.5 mL/cm3) and 
18F-PBR111 (2.22-4.03 mL/cm3) (36,37). 18F-LW223 SUV brain values in rats (ranging 
between 0.5-1.3 mg/mL over time) also compared  favourably with 11C-PK11195 (0.6-0.8 
mg/mL) (38) in the same species. Comparison of 18F-LW223 performance in mapping 
TSPO in heart and lung is more challenging owing to limited data on previously developed 
TSPO PET radiotracers outside the brain. Still, 18F-LW223 SUV in rat heart and lung (3.5-
4.5 and 3-3.5, respectively) also compared positively with 11C-PK11195 (peak SUV in 
heart of 5 and in lung of 3) in humans (39). Importantly, 18F-LW223 has a considerably 
high fp of 38.5% compared to 11C-PBR28 (21%) (40) in rats; and 11C-PBR28 (3-11%) (16), 
11C-PK11195 (1%) (41) and 11C-ER176 (3.3%) (36) in humans. 18F-LW223 also has an 
excellent radiometabolic profile (62% parent at 120 min in plasma) which is higher than 
11C-PK11195 (c. 40%, (42) in the same lower species). The measured radiometabolites 
in plasma were less lipophilic than the parent compound, suggesting they would have 
lower brain penetration. This is confirmed by the low fraction of radiometabolites 
measured in brain tissue and other target organs, which will minimally impact on in vivo 
PET data quantification. 18F-LW223 binding to TSPO in vivo was blocked and displaced 
by PK11195, indicating the specificity of this novel ligand for TSPO. The estimated 
dosimetry of 18F-LW223 (0.020 mSv/MBq) was also well within typical values for 18F-
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labeled radiotracers currently in routine clinical use (e.g. 18F-FDG 0.029 mSv/MBq (43)), 
therefore easing translation to humans.  
An additional aim of this study was to develop a novel multi-parametric analysis 
approach which would allow for accurate quantification of regional TSPO expression 
within the infarcted myocardium with a single scan paradigm. We utilized dynamic 
imaging and 2TCM to quantify the different rate kinetics of the 18F-LW223 signal. 
Traditionally, 2TCM is used to calculate VT (19). Our data demonstrated that the drop in 
K1 was severely perturbed within the infarct region to a far greater extent than the other 
constants, particularly k2. Due to the imbalanced decrease in movement of radiotracer 
from the blood into the tissue (K1) and the reverse (k2), and the fact during these 
hypoperfused conditions K1→F, VT was not able to reflect disease activity accurately. For 
our high affinity ligand, 18F-LW223, and in the highly hypoperfused and inflamed 
myocardium, the result is a violation of the Michaelis-Menten free ligand approximation 
principle. In these circumstances, the Morrison kinetics of tight binding reversible ligands 
apply (44,45). 
Our reported K1 values (Supplementary Table.4) were relatively high in the heart 
and lung but not in the brain, which indicates that the respective PS is also high for 18F-
LW223 and thus support the K1→F assumption. Moreover, our in vivo modelling data are 
also corroborated by ex vivo tissue analysis with PET-independent measures of antibody-
tagged TSPO immunofluorescence. 18F-LW223 can be classified as a moderately 
extracted radiotracer if we use 15O-water as a benchmark for high extraction. Therefore, 
theoretically, for large flows (e.g. healthy myocardium) deviation of apparent K1 (i.e. 
flow×extraction) from the flow line of identity would be more pronounced than low flows 
by on October 12, 2020. For personal use only. jnm.snmjournals.org Downloaded from 
21 
 
(e.g. infarcted region) (46). This is in fact similar and expected behavior to routinely used 
SPECT or PET myocardial perfusion agents (e.g. 99mTc-Sestamibi or 18F-Flurpiridaz) (47).   
Previously this hemodynamic change following MI has been corrected using an 
additional  SPECT scan (6), resulting in an increased cost and patient burden. Here we 
derived BPTC as a new outcome measure for quantification of the TSPO PET signal using 
a single-scan protocol. Currently, we make use of the gold standard invasive arterial 
sampling for data quantification, although this is not always practical in a clinical setting. 
With the validation of BPTC using ex-vivo histology, clinical translation can now take place 
using simplified non-invasive image derived input function (IDIF) to derive robust outcome 
measures in line with our previously reported findings (48). 
Our simulation work using ideal noise-free conditions shows that in areas of low 
BPND (a proxy for TSPO brain uptake), the reduction of K1 needs to be much higher than 
in areas of expected high BPND (a proxy for TSPO heart uptake) to impact BPND 
measures. Sander et al. have recently reported that large K1 and small k2 values (i.e. 
large volume of distribution, VD) are most sensitive to changes in blood flow (49). This is 
in line with our data and point out important differences when assessing radiotracer 
binding in the heart (where VD is high) versus the brain (where VD is low). Therefore, even 
though minor BPND changes in the brain were reported by Sander et al. due to cerebral 
blood flow increases up to 100% mid-scan, these observations might not translate directly 
to other organs and hypoperfusion scenarios as oppose to hyperperfusion. In particular, 
studies have shown that following MI, vascular remodelling includes regional vasodilation, 
vasoconstriction, or pruning. All of these have been shown to impact on microvascular 
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conductivity (50); which could contribute to imbalanced K1 versus k2 changes beyond flow 
changes.  
Previous studies using chemokine receptor type 4 (CXCR-4) radiotracers, an 
alternative inflammatory target, have shown that the highest radiotracer signal was 
detected in areas of infarct at 3 days post-MI without perfusion correction (51,52). 
Differences between these studies and ours may be due to the difference in target, size 
of radiotracer molecule, experimental model and time point assessed. These last two 
points result in considerable differences in blood flow, haemodynamic responses and 
tissue remodelling stages which will impact imaging outcomes. 
In the rat MI model used in this study, we demonstrated that the majority of TSPO 
expression (BPTC) was within the infarct region of the MI cohort, which was in agreement 
with ex-vivo analysis.  However, it should be noted that in non-infarcted myocardium in 
other MI/cardiomyopathy models of heart failure, there is significant TSPO expression, 
indicating that TSPO may have a wider role in the failing heart (53,54). 
A limitation in our study is that we only assessed one time point in our MI study. 
Follow up studies with longitudinal TSPO imaging following MI in rats are being planned 
which will be necessary to robustly assess the transient nature of inflammation and this 
molecular target. In addition, it is currently not clear whether targeting TSPO in 
macrophages is selective for M1 or M2 phenotypes, with previous evidence being 
conflicted on this aspect (6,55,56). This is something which we also plan to address in 
our follow-up studies in addition to selectivity of 18F-LW223 for different leukocyte 
subpopulations as has been previously carried out (6). Another limitation of our study is 
that we have only carried out radiometabolite analysis of 18F-LW223 in naive rats. Our 
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data suggests there are no significant differences in radioactive concentration in blood of 
naïve versus MI animals, however, it is possible that the metabolite profile of 18F-LW223 
changes during MI and this could affect the PET outcome measures. 
With the advent of total-body PET clinical scanners (57), assessment of multi-
organ responses to disease will become increasingly important in medical research. This 
is attractive for TSPO-PET studies, given that TSPO has served as a marker of regional 
tissue inflammation in pathologies throughout the body (4,6–10). In this study, we 
observed a significant positive correlation between the brain and heart following MI, which 
was detected by 18F-LW223 PET imaging in vivo, and TSPO and CD68 staining ex-vivo. 
Additionally, our ex-vivo results demonstrated a trend towards increased TSPO 
expression staining in the whole brain post-MI, albeit without reaching significance. The 
degree of the change was small, and similar to the change previously reported by 
Thackeray et al. (6). However, at a regional level there was increased expression in TSPO 
within the lateral ventricles. It is possible that the increased signal in the brain is due to 
blood-brain-barrier hyper-permeability and dysfunction of the blood-cerebrospinal fluid 
system, which exist to preserve central nervous system homeostasis (58). This is 
corroborated by the increase in TSPO expression we observed in the lateral ventricles 
and agrees with previous studies demonstrating the role of the choroid plexus in the 
recruitment of macrophages at distant sites (59,60). At a cellular level, although some 
TSPO expression co-localized with the CD68 marker in the brain, there were cells positive 
for TSPO that lacked co-expression with CD68. This is to be expected, as TSPO is 
expressed in a number of brain cell types (61). Overall, our results with 18F-LW223 PET 
in this rat model of MI corroborate the findings by Thackeray et al. in mice and humans, 
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thus echoing the importance of integrative systems biology analysis in PET studies (6). 
The clinical importance of the heart:brain axis following MI is not yet clear and should be 
investigated further. 
In conclusion, we have developed a novel TSPO radiotracer which is not 
susceptible to the rs6971 human genetic polymorphism in addition to an original multi-
parametric analysis approach. These tools now warrant further investigation and 
translation in the fields of cardiology and neurology.  
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Key Points 
QUESTION 
Is our newly developed TSPO radiotracer, 18F-LW223¸ able to detect macrophage-
driven inflammation following myocardial infarction while being suitable for clinical 
translation and not affected by the rs6971 human genetic polymorphism? 
PERTINENT FINDINGS: 
Binding of 18F-LW223 to TSPO in human brain and heart in vitro assays demonstrated 
that it was not susceptible to the rs6971 genetic polymorphism; while the preclinical in 
vivo characterisation indicated that 18F-LW223 is specific, has favourable metabolism 
and a dosimetry profile suitable for translation. In a preclinical rat myocardial infarction 
model 18F-LW223 BPTC was significantly increased within the infarct relative to naive 
myocardium, which mirrored the pattern of macrophage expression in these animals 
detected by ex-vivo immunofluorescent staining. 
IMPLICATIONS FOR PATIENT CARE: 
As 18F-LW223 is not affected by the rs6971 human genetic polymorphism, and has 
excellent in vivo characteristics, it is a prime candidate for further clinical translation 
which could ultimately lead to the development of a prognostic tool for use in patients 
following myocardial infarction. 
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Figures 
 
 
Figure 1. Radiosynthesis of 18F-LW223. Data shown as the mean± SEM. 
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Figure 2. LW223 binding to TSPO is not affected by the human rs6971 genetic 
polymorphism. A) Chemical structures of established (PK11195, PBR28) and novel 
(AB5186, LW223) TSPO ligands investigated. B) Competition binding assays using the 
above TSPO ligands in human brain homogenates genotyped and grouped as HAB, MAB 
and LAB. PK11195 HAB n = 6, MAB=8, LAB=4, PBR28 HAB n = 4, MAB (two-site 
fitting)=5, LAB=4, AB5186 HAB n = 6, MAB (two-site fitting)=6, LAB=5 and LW223 HAB 
n = 5, MAB=5, LAB=4. Only PK11195 and LW223 were not affected by the polymorphism, 
which is also demonstrated in C) human heart homogenates. PK11195 HAB n = 4, 
MAB=5, LAB=4, PBR28 HAB n = 4, MAB=5, LAB=4, AB5186 HAB n = 4, MAB=5 (two-
site fitting), LAB=4 and LW223 HAB n = 5, MAB=5, LAB=4. 
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Figure 3.  18F-LW223, assessed in naive rats, has a favorable metabolic profile and 
specifically targets TSPO in vivo. A) Left: Maximum intensity projection of an 18F-
LW223 PET scan in a naive rat showing the major uptake organs, B=brain, L=lung, 
H=heart, G=gut, A=adrenal glands, K=kidney. Middle: Metabolism of 18F-LW223 within 
rat blood showing a high percentage of parent radiotracer within plasma up to 2 hours 
post injection, n = 3 per time point. Right: Percentage of parent radiotracer within different 
tissues demonstrating a low level of contaminating radiometabolites, n = 3. B) SUV 
images of the rat heart (Left), lung (Middle) and brain (Right) at baseline (left panel) and 
under TSPO blockade using the prototypical TSPO ligand PK11195 (1 mg/kg, right panel) 
demonstrating the specificity of 18F-LW223 for this target. SUV PET images were filtered 
using a Gaussian 1×1×1 mm filter. C) Total distribution volume (VT) within the heart (Left) 
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lung (Middle) and brain (Right) of naive and TSPO-blocked rats. Results represent the 
mean±SEM, naive n = 6, blocked n = 3, *=p<0.05, **=p≤0.01, ***=p≤0.001 using an 
unpaired t-test.  
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Figure 4. 18F-LW223 PET with BPTC quantification detects macrophage-driven 
inflammation within the heart 7 days post-MI without the need for an additional 
perfusion scan. A) Left: A long axis representative SUV image of the heart in naive and 
MI rats showing increased global uptake and lack of signal within the left ventricle (LV) 
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anterior wall due to the MI-mediated reduction in perfusion. R=right side, L=left side. 
Images were filtered using a Gaussian 1×1×1 mm filter. Middle: Non-perfusion corrected 
volume of distribution (VT) measurements within the global heart and LV anterior wall 
which was the site of infarct. Right: The rate constant K1 acts as a surrogate marker of 
perfusion and is reduced within the LV anterior wall. B) Left: Representative K1 and 
transfer corrected BPND (BPTC) images (Middle) of the left ventricle of an MI rat 
demonstrating the true TSPO signal across the heart. A=anterior and P=posterior. Right: 
BPTC values across the global heart and LV anterior wall demonstrating that the majority 
of TSPO is expressed within the infarct. C) Representative histology examples of hearts 
from a naive (top row) and MI (bottom row) rat. The left panel is a H&E overview (scale 
bar=1000 µm) containing a box which indicates the position of the CD68 (macrophage 
marker) and TSPO examples (scale bar= 50 µm) demonstrating the specificity of TSPO 
for macrophages which are mostly present within the infarct. D) Left: Quantification of the 
TSPO immunofluorescent stain indicating that the majority of the signal is present within 
the LV anterior wall, as is also the case with the CD68 quantification (Middle). Right: 
Comparison of TSPO and CD68 indicates a significant correlation within the heart. 
Results represent the mean±SEM, n = 6 for naive, n = 5 for MI. **=p≤0.01, ***=p≤0.001 
and ****= p≤0.0001 using a two-way ANOVA with post-hoc Sidak for naive vs. MI apart 
from the correlation analysis which used Pearson correlation. 
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Figure 5. The heart: brain axis in health and following myocardial infarction. A) Left 
Row: Representative 18F-LW223 brain (coronal section) and heart (short axis) PET/CT 
images of naive and MI rats.  Middle Row: CD68 (red) and TSPO (green) 
immunofluorescence within the same animals, scale bar=1000 µm. Right Row: Regional 
brain immunofluorescence within the lateral ventricles of naive (top) and MI (second top). 
Regional brain immunofluorescence within the thalamus of naive (second to bottom) and 
MI (bottom), scale bar=20 µm. White arrow denotes cells which are both CD68 and TSPO 
positive, the pink arrow indicates cells positive only for CD68. Cells positive only for TSPO 
were abundant and are not specifically denoted.  B) Top: Comparison of 18F-LW223 VT 
in the heart and brain of naive and MI rats showing a strong correlation, as is also the 
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case for TSPO (Middle) and CD68 (Bottom). **=p≤0.01, **=p≤0.0001 using Pearson 
correlation. 
 
Estimated Absorbed Dose  
 ×10−2 mGy/MBq 
Target Organ Male Female 
Adrenals 2.22 3.67 
Brain 0.59 0.56 
Breasts 0.72 0.86 
Gallbladder Wall 2.01 2.46 
LLI Wall 7.82 9.26 
Small Intestine 1.11 1.30 
Stomach Wall 0.94 1.15 
ULI Wall 1.00 1.24 
Heart Wall 2.03 1.89 
Kidneys 1.57 1.54 
Liver 1.30 1.95 
Lung 3.10 3.31 
Muscle 0.80 0.98 
Ovaries - 1.66 
Pancreas 1.03 1.26 
Red Marrow 0.82 0.98 
Osteogenic Cells 1.20 1.52 
Skin 0.61 0.74 
Spleen 0.91 1.11 
Testes 0.77 - 
Thymus 0.90 1.07 
Thyroid 0.79 0.89 
Urinary Bladder Wall 1.16 1.48 
Uterus - 1.29 
Total Body 0.89 1.07 
Effective Dose (mSv/MBq) 0.02 0.02 
 
Table 1. Estimated 18F-LW223 radiation dose for humans is within acceptable limits 
for future clinical use. LLI=lower large intestine, ULI=upper large intestine, male n = 8, 
female n = 5. 
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SUPPLEMENTAL METHODS 
Organic Chemistry 
All reagents and starting materials were obtained from commercial sources and used as 
received. All dry solvents were purified using a PureSolv 500 MD solvent purification 
system. All reactions were performed under argon unless otherwise stated. Brine is 
defined as a saturated solution of aqueous sodium chloride. Flash column 
chromatography was carried out using Fisher Matrix silica 60. Macherey–Nagel 
aluminium–backed plates pre–coated with silica gel 60 (UV254) were used for thin layer 
chromatography and were visualized using UV light. 1H NMR and 13C NMR spectra were 
recorded on a Bruker DPX 400 spectrometer or Bruker 500 spectrometer with chemical 
shift values in ppm relative to tetramethylsilane (δH 0.00 and δC 0.0) or residual chloroform 
(δH 7.26 and δC 77.2) as the standard. 1H and 13C assignments are based on two-
dimensional COSY and DEPT experiments, respectively. Infrared spectra were recorded 
on a JASCO FTIR 410 spectrometer. Mass spectra were recorded using electron impact, 
chemical ionization or fast atom bombardment techniques. HRMS spectra were recorded 
using a dual-focusing magnetic analyzer mass spectrometer. Melting points were 
determined on a Gallenkamp melting point apparatus. Chiral High Performance Liquid 
Chromatography (HPLC) methods were calibrated with the corresponding racemic 
mixtures. 3-Methyl-4-phenylquinoline-2-carboxylic acid was prepared as previously 
reported (14). 
 
 (R)-(N-sec-Butyl)-3-methyl-4-phenylquinoline-2-carboxamide 
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To a solution of 3-methyl-4-phenylquinoline-2-carboxylic acid (2.54 g, 9.65 mmol) in 
anhydrous N,N-dimethylformamide (250 mL) was added O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (5.49 g, 14.5 mmol) and N,N-
diisopropylethylamine (3.40 mL, 19.3 mmol). The reaction mixture was stirred at room 
temperature for 0.5 h before the addition of (R)-(−)-sec-butylamine (1.10 mL, 10.6 mmol) 
and then heated to 40 °C for 4 h. The reaction mixture was cooled to room temperature, 
diluted with ethyl acetate (300 mL) and washed with water (3 × 200 mL) and brine (200 
mL). The organic layer was dried (MgSO4), filtered and concentrated in vacuo to give a 
brown oil. Purification by flash column chromatography (petroleum ether/ethyl acetate, 
4:1) gave (R)-(N-sec-butyl)-3-methyl-4-phenylquinoline-2-carboxamide as a white solid 
(2.81 g, 91%). Mp 152–154 °C (lit.(15) mp 157–158 °C); IR (KBr) 3287 (NH), 2968 (CH), 
1641 (CO), 1539, 1448, 1157, 761 cm–1; [α]D25 –26.7 (c 1.0, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 1.03 (3H, t, J = 7.4 Hz, CHCH2CH3), 1.33 (3H, d, J = 6.6 Hz, CHCH3), 1.61–
1.75 (2H, m, CH2CH3), 2.56 (3H, s, 3-CH3), 4.08–4.20 (1H, m, CHCH3), 7.21–7.25 (2H, 
m, ArH), 7.35 (1H, d, J = 8.3 Hz, ArH), 7.40–7.55 (4H, m, ArH), 7.65 (1H, ddd, J = 8.3, 
6.8, 1.4 Hz, ArH), 7.90 (1H, d, J = 8.3 Hz, NH), 8.09 (1H, d, J = 8.3 Hz, ArH); 13C NMR 
(101 MHz, CDCl3) δ 10.6 (CH3), 17.6 (CH3), 20.5 (CH3), 29.9 (CH2), 46.8 (CH), 126.1 
(CH), 127.5 (CH), 127.9 (CH), 128.6 (C), 128.6 (2 × CH), 128.7 (CH and C), 129.3 (2 × 
CH), 129.5 (CH), 137.3 (C), 144.7 (C), 149.5 (C), 150.1 (C), 166.2 (C); MS (CI) m/z 319 
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(M+H+, 100%), 220 (19), 202 (5), 148 (6), 113 (16), 85 (77); HRMS (CI) calcd for 
C21H23N2O (M+H+), 319.1810, found 319.1809. 
 
(R)-(N-sec-Butyl)-N-methyl-3-methyl-4-phenylquinoline-2-carboxamide 
 
To a solution of (R)-(N-sec-butyl)-3-methyl-4-phenylquinoline-2-carboxamide (2.81 g, 
8.82 mmol) in tetrahydrofuran (176 mL) was added sodium hydride (60% dispersion in 
mineral oil, 0.710 g, 17.6 mmol). The mixture was stirred at room temperature for 0.5 h, 
before the addition of iodomethane (2.75 mL, 44.1 mmol). The resultant solution was 
stirred at room temperature for 3 h and then quenched by addition of water. The aqueous 
phase was extracted with diethyl ether (3 × 10 mL). The combined organic phases were 
washed with a 10% aqueous solution of sodium thiosulfate (10 mL), brine (10 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (petroleum ether/ethyl acetate, 3:1) gave (R)-(N-sec-butyl)-N-methyl-3-
methyl-4-phenylquinoline-2-carboxamide as a white solid (2.75 g, 94%). NMR spectra 
showed a 1:1 mixture of rotamers. Signals for both rotamers are recorded. Mp 114–117 
°C (lit.(15) mp 117–118 °C); IR (KBr) 2969 (CH), 1637 (CO), 1466, 1072, 731 cm–1; [α]D23 
–6.3 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.86 (3H, t, J = 7.3 Hz, CH2CH3), 1.03 
(3H, t, J = 7.3 Hz, CH2CH3), 1.24 (3H, d, J = 6.6 Hz, CHCH3), 1.28 (3H, d, J = 6.6 Hz, 
CHCH3), 1.36–1.71 (4H, m, 2 × CH2CH3), 2.21 (3H, s, 3-CH3), 2.23 (3H, s, 3-CH3), 2.73 
(3H, s, NCH3), 3.04 (3H, s, NCH3), 3.42–3.53 (1H, m, CHCH3), 4.84–4.94 (1H, m, 
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CHCH3), 7.25–7.31 (4H, m, ArH), 7.38–7.44 (4H, m, ArH), 7.45–7.57 (6H, m, ArH), 7.60–
7.67 (2H, m, ArH), 8.09 (1H, d, J = 8.3 Hz, ArH), 8.11 (1H, d, J = 8.3 Hz, ArH); 13C NMR 
(101 MHz, CDCl3) δ 11.2 (CH3), 11.3 (CH3), 16.0 (CH3), 16.4 (CH3), 17.3 (CH3), 18.6 
(CH3), 25.5 (CH3), 26.5 (CH3), 27.2 (CH2), 29.3 (CH2), 49.6 (CH), 55.8 (CH), 124.6 (C), 
125.3 (C), 125.9 (CH), 126.0 (CH), 126.7 (2 × CH), 126.8 (2 × CH), 127.4 (2 × C), 128.0 
(2 × CH), 128.6 (2 × CH), 128.7 (2 × CH), 129.2 (4 × CH), 129.4 (2 × CH), 136.7 (C), 
136.8 (C), 145.8 (C), 146.1 (C), 148.0 (C), 148.1 (C), 156.1 (C), 156.6 (C), 169.4 (C), 
169.7 (C); MS (CI) m/z 333 (M+H+, 100%), 291 (48), 250 (41), 220 (14), 86 (23); HRMS 
(CI) calcd for C22H25N2O (M+H+), 333.1967, found 333.1972.  
 
(R)-3-Bromomethyl-(N-sec-butyl)-N-methyl-4-phenylquinoline-2-carboxamide  
 
To a stirred, degassed solution of (R)-(N-sec-butyl)-N-methyl-3-methyl-4-
phenylquinoline-2-carboxamide (2.70 g, 8.12 mmol) in chloroform (300 mL) was added 
N-bromosuccinimide (2.17 g, 12.2 mmol) and dibenzoyl peroxide (0.20 g, 0.812 mmol) 
and the solution heated under reflux for 6 h. A further portion of N-bromosuccinimide (1.00 
g, 5.61 mmol) was then added and the solution heated under reflux for a further 16 h. The 
reaction mixture was cooled to room temperature, filtered and the solvent removed in 
vacuo. The crude residue was then diluted with ethyl acetate (100 mL) and washed with 
water (3 × 100 mL). The organic layer was dried (MgSO4), filtered and concentrated in 
vacuo. Purification by flash column chromatography using a graduated eluent of 
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dichloromethane > dichloromethane/ethyl acetate (95:5) afforded (R)-3-bromomethyl-(N-
sec-butyl)-N-methyl-4-phenylquinoline-2-carboxamide as an orange solid (2.8 g, 85%). 
NMR spectra showed a 2:1 mixture of rotamers. Only signals for the major rotamer are 
recorded. Mp 160–164 °C; IR (KBr) 2970 (CH), 1631 (CO), 1484, 1397, 1046, 766 cm–1; 
[α]D28 –9.0 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.09 (3H, t, J = 7.4 Hz, CH2CH3), 
1.32 (3H, d, J = 6.8 Hz, CHCH3), 1.51–1.80 (2H, m, CH2CH3), 2.86 (3H, s, NCH3), 4.60 
(1H, d, J = 10.2 Hz, 3-CHH), 4.67 (1H, d, J = 10.2 Hz, 3-CHH), 4.87 (1H, sextet, J = 6.8 
Hz, CHCH3), 7.37–7.48 (4H, m, ArH), 7.51–7.59 (3H, m, ArH), 7.70 (1H, ddd, J = 8.3, 6.7, 
1.5 Hz, ArH), 8.10 (1H, dd, J 8.8, 8.3 Hz, ArH); 13C NMR (101 MHz, CDCl3) δ 11.1 (CH3), 
17.1 (CH3), 26.6 (CH2), 27.7 (CH2), 30.5 (CH3), 50.1 (CH), 126.3 (C), 126.7 (2 × CH), 
127.4 (CH), 128.6 (2 × CH), 128.7 (CH), 129.0 (CH), 129.1 (CH), 129.5 (CH), 130.1 (C), 
134.9 (C), 146.4 (C), 149.3 (C), 156.0 (C), 168.4 (C); MS (EI) m/z 410 (M+, 5%), 298 (15), 
296 (14), 217 (57), 189 (28), 151 (10), 86 (100); HRMS (EI) calcd for C22H2379BrN2O (M+), 
410.0994, found 410.0992.  
 
(R)-(N-sec-Butyl)-3-chloromethyl-N-methyl-4-phenylquinoline-2-carboxamide  
 
To a solution of (R)-3-bromomethyl-(N-sec-butyl)-N-methyl-4-phenylquinoline-2-
carboxamide (0.500 g, 1.22 mmol) in dry tetrahydrofuran (10 mL) was added lithium 
chloride (0.160 g, 3.66 mmol) and the reaction mixture stirred at room temperature for 16 
h. The reaction was quenched with water (30 mL) and extracted into ethyl acetate (3 × 
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30 mL). The organic layers were combined and washed with brine (90 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The product was purified by flash column 
chromatography (dichloromethane/ethyl acetate, 95:5) to afford (R)-3-chloromethyl-(N-
sec-butyl)-N-methyl-4-phenylquinoline-2-carboxamide as a white solid (0.331 g, 74%). 
NMR spectra showed a 1.5:1 mixture of rotamers. Only signals for the major rotamer are 
recorded. Mp 140–142 °C; IR (neat) 2970 (CH), 1620 (CO), 1481, 1404, 1219, 748 cm–
1; [α]D24 –11.6 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.08 (3H, t, J = 7.4 Hz, 
CH2CH3), 1.30 (3H, d, J = 6.8 Hz, CHCH3), 1.49–1.79 (2H, m, CH2CH3), 2.84 (3H, s, 
NCH3), 4.67 (1H, d, J = 10.6 Hz, 3-CHH), 4.72 (1H, d, J = 10.6 Hz, 3-CHH), 4.82–4.92 
(1H, m, CHCH3), 7.36–7.61 (7H, m, ArH), 7.69–7.75 (1H, m, ArH), 8.11 (1H, dd, J 9.0, 
8.4 Hz, ArH); 13C NMR (101 MHz, CDCl3) δ 11.1 (CH3), 17.1 (CH3), 26.6 (CH2), 30.4 
(CH3), 40.4 (CH2), 50.1 (CH), 125.8 (C), 126.8 (CH), 127.2 (C), 127.4 (CH), 128.5 (2 × 
CH), 128.7 (CH), 129.4 (CH), 129.6 (2 × CH), 130.1 (CH), 134.9 (C), 146.6 (C), 149.5 
(C), 156.1 (C), 168.5 (C); MS (ESI) m/z 389 (M+Na+, 100%); HRMS (ESI) calcd for 
C22H2335ClN2NaO (M+Na+), 389.1391, found 389.1381. 
 
(R)-(N-sec-Butyl)-3-fluoromethyl-N-methyl-4-phenylquinoline-2-carboxamide  
 
To a solution of 18-crown-6 (0.032 g, 0.12 mmol) in acetonitrile (2.5 mL) was added 
potassium fluoride (0.036 g, 0.61 mmol) and the resulting suspension stirred at room 
temperature for 0.5 h. A solution of (R)-3-bromomethyl-(N-sec-butyl)-N-methyl-4- 
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phenylquinoline-2-carboxamide (0.050 g, 0.12 mmol) in acetonitrile:dichloromethane 
(2:1, 9.0 mL) was then added dropwise and the reaction mixture heated under reflux for 
72 h. Upon completion, the reaction mixture was cooled to ambient temperature and 
water (20 mL) was added. The solution was extracted with dichloromethane (3 × 20 mL), 
dried (MgSO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography (petroleum ether/ethyl acetate 7:3) gave (R)-N-(sec-butyl)-3-
(fluoromethyl)-N-methyl-4-phenylquinoline-2-carboxamide as a white solid (0.029 g, 
67%). NMR spectra showed a 3:1 mixture of rotamers. Only signals for the major rotamer 
are recorded. Mp 146–148 °C; IR (neat) 2972 (CH), 1628 (CO), 1559, 1485, 1398, 1049, 
970 cm−1; [α]D30 –12.6 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.05 (3H, t, J = 7.4 
Hz, CH2CH3), 1.29 (3H, d, J = 6.8 Hz, CHCH3), 1.41–1.78 (2H, m, CH2CH3), 2.77 (3H, s, 
NCH3), 4.84–4.95 (1H, m, NCH), 5.31 (1H, dd, J 20.8, 10.8 Hz, 3-CHH), 5.44 (1H, dd, J 
20.8, 10.8 Hz, 3-CHH), 7.31–7.40 (2H, m, ArH), 7.43–7.58 (5H, m, ArH), 7.74 (1H, t, J 
7.6 Hz, ArH), 8.17 (1H, d, J 8.4 Hz, ArH); 13C NMR (101 MHz, CDCl3) δ 10.9 (CH3), 17.4 
(CH3), 26.5 (CH3), 29.9 (CH2), 50.0 (CH), 79.2 (CH2, 1JC–F = 162.8 Hz), 123.0 (C, 2JC–F = 
15.1 Hz), 127.0 (CH), 127.1 (C, 4JC–F = 2.3 Hz), 127.4 (CH, 5JC–F = 1.2 Hz), 128.5 (2 × 
CH), 128.7 (CH), 129.6 (2 × CH), 129.7 (CH), 130.4 (CH), 134.8 (C, 4JC–F = 1.5 Hz), 147.4 
(C, 3JC–F = 2.5 Hz), 150.8 (C, 3JC–F = 4.7 Hz), 156.6 (C, 5JC–F = 2.1 Hz), 168.8 (C); MS 
(ESI) m/z 373 (M+Na+, 100%); HRMS (ESI) calcd for C22H23FN2NaO (M+Na+), 373.1687, 
found 373.1670. Enantiomeric excess was determined by HPLC analysis with a chiralcel 
AD-H column (hexane:iPrOH 97.5:2.5, flow rate 1.0 mL/min), tmajor = 30.68 and 32.22 min, 
tminor = 27.15 and 38.38 min; er = 99.5:0.5. 
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In Vitro Human Competition Binding Assays 
Briefly, 250 µg protein/mL in 200 µl of buffer was added to 100 µl of 1 nM 3H-
PK11195 (PerkinElmer, USA), together with 100 µl of test ligands PK11195 (Sigma-
Aldrich, USA), PBR28 (ABX, Germany), AB5186 or LW223 at 14 different concentrations 
(0.001-3000 nM) for 90 min at 4 ºC. Binding was terminated with the addition of ice cold 
buffer before being immediately filtered over a Whatman GF/B filters (Whatman, UK) pre-
treated with 0.3% polyethylenimine (Sigma-Aldrich, USA) using a Brandel harvester 
(Brandel, USA). Filter paper was then removed, placed into 2.5 mL of Optiphase HiSafe 
3 (Perkin Elmer, USA) and counted 48 hours later on a Hidex 300 SL (Hidex, Finland). 
Saturation assays were performed to determine the Kd of PK11195 using a similar 
protocol, except that 6 concentrations of 3H-PK11195 (1.6-200 nM) were used alongside 
10 µM of PK11195 to determine non-specific binding. All binding assays were performed 
in triplicate. 
GraphPad Prism version 6 (GraphPad Software, USA) was used to fit all binding 
affinity curves. A comparison of a one-site and two-site models was made using the least 
squares algorithm and model selection was compared using an F test. The null 
hypothesis (one-site fitting as more suitable) was rejected if p<0.05. Normalized mean 
%SB of each group (HAB, MAB or LAB) and a Kd value of 14.0nM (determined based on 
saturation binding results, Sup.Fig.2) was used to determine the best fitting model and to 
calculate LAB:HAB ratios. Affinity values (Ki) were calculated by fitting individual tissue 
samples again with a Kd 14.0nM. 
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Invasive Input Function Measurement 
Polyethylene catheters (PE50) filled with heparinized saline (20 IU/mL) were 
inserted into the left femoral artery and vein with the help of a stereomicroscope and 
securely fastened with ligatures (6-0 silk thread). Catheters were held in place with 
surgical glue.   
 
Rat Myocardial Infarction Procedure 
Briefly, the skin was incised at the level of the left third and fourth ribs where the 
pectoral muscles were divided and retracted. Left lateral thoracotomy was then 
performed. With minimal handling, the pericardium was ruptured and the heart gently 
exteriorized from the thorax, and a nonabsorbable 5-0 ligature was placed around the left 
anterior descending coronary artery just above the bifurcation of the first diagonal and 
maneuvered back into position. Before wound closure, a drain was inserted to assist with 
removal of air and fluid from the thorax. Once removed, the wound was then closed in 
three layers. Animals were recovered and extubated once spontaneous ventilation was 
established, housed at 30 °C for 24 hours and given sterile sodium chloride 0.9% 0.01 
mL/g fluid therapy subcutaneously in addition to another dose of Buprenorphine. After 24 
hours, normal housing conditions were resumed.  
 
Radiometabolite Blood and Tissue Processing and Analysis 
All blood samples were 1 mL each and manually collected from different animals 
to generate a population curve, in order to respect total blood volume limits for terminal 
arterial blood collections in rats. Following blood and tissue collection, all samples were 
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kept on ice until analyzed. Radioactivity in whole blood and plasma, as well as 
homogenized tissue samples, was assessed using a well-type γ-counter using a 400–
1400 keV window (Perkin Elmer Wizzard2, USA). Plasma samples (400 μl) and tissue 
samples (500 μl) were processed by acetonitrile denaturation (1:1.4 v/v) and analyzed by 
HPLC (Ultimate2000, ThermoFisher, UK) on a Luna C18(2) 10×250 mm, 10 μm column 
(Phenomenex, UK) with acetonitrile/water 70/30 and flow rate of 4 mL/min to estimate the 
parent fraction. The plasma fp was determined using ultrafiltration units (Centrifree® 30K, 
Millipore, UK). 
 
Simulation of Changes in 18F-LW223 BPND for varying blood flow scenarios  
Simulation work was carried out using a Matlab (MathWorks, USA) 2-tissue compartment 
code with Ordinary Differential Equation (ODE) solvers. Six different levels of K1 values 
(0.9, 0.7, 0.5, 0.3, 0.1 and 0.01 mL/min/cc) were tested with fixed k2 and vB=0.05. The 
following BPND values were simulated: 4, 10, 16 and 20; with k3 modified and k4 fixed. All 
micro parameters used in the simulations are shown in Supplemental Table 5. The input 
function used was an average of the blood curves taken from healthy animals using the 
SwissTrace blood sampler (Supplemental  Data File 1). The plasma to whole blood ratio 
used was 1.84 and the AIF was metabolite corrected using a population based curve as 
in the experimental data. All modelled time-activity curves were noise free. Outcome 
measures were estimated using Turku code (fitk4, 
http://www.turkupetcentre.net/petanalysis/tpcclib/doc/fitk4.html) and operational 
equations for 2-tissue curve fitting. The minimisation code used Topographical Global 
Optimisation based on an algorithm by Aimo Torn and Sami Viitanen 
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(www.abo.fi/~atorn/ProbAlg/Page53.html).  Calculated BPND for each simulated scenario 
was compared with truth BPND. All parameters estimated with the parameter standard 
deviation for K1 and BPND are reported in Supplemental Table 6. 
 
Ex Vivo Immunofluorescence Imaging 
Briefly, antigen retrieval was carried out in a pressure cooker using tris-EDTA (pH 
9) before an endogenous peroxidase block (3% H2O2, 15 min) and tissue 
permeabilization/ blocking in 10% donkey serum (PBS, 0.1% Triton X-100) for 1 hour 
room at temperature. The CD68 primary antibody (1/100 in 1% donkey serum, MCA341R, 
Bio-Rad, USA) was incubated with the slides overnight at 4 °C, followed by incubation 
with the first secondary antibody (1/750 in 1% donkey serum, donkey anti-mouse-HRP, 
715-036-150, Jackson ImmunoResearch, USA) for 1 hour at room temperature. This first 
secondary antibody was visualized using the TSA system (Cyanine 3 System, 1/50 for 4 
min, Perkin Elmer, UK). Microwave antigen retrieval (tris-EDTA pH 9) was then carried 
out to destroy the CD68-associated antibodies, leaving behind the visualization product 
only. An additional endogenous peroxidase and serum block was performed before 
incubation with the TSPO primary antibody (1/100 in 1% donkey serum, ab109497, 
Abcam, UK) for 1 hour at room temperature. A subsequent secondary antibody incubation 
was performed at 1 hour room temperature (1/750 in 1% donkey serum, donkey anti-
rabbit-HRP, 711-036-152, Jackson ImmunoResearch, USA) before visualization with the 
TSA reagent (Cyanine 5 System, 1/50 for 4 min, Perkin Elmer, UK). The slides were then 
counterstained with DAPI and mounted. 
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Autoradiography 
Rehydrated tissue on glass slides was incubated in assay buffer (50 mM Tris Buffer) for 
30 min prior to the experiment. The slides were then incubated with 18F-LW223 (50 nM in 
assay buffer) for 1 hour at room temperature. Slides were washed twice in assay buffer 
followed by a dip in dH2O. The slides were then dried and exposed to an autoradiography 
plate (BAS-IP-SR 2040 super resolution screen, Cytiva, USA) and imaged on an 
autoradiography imager (Amersham Typhoon IP Biomolecular Imager, Cytiva, USA).  
Images were analyzed using Image J, using the ratio of signal within a ROI to the 
background signal on each slide to calculate the tissue to background ratio (TBR). 
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SUPPLEMENTARY RESULTS 
 
 
 
Supplemental Figure. 1. Four step synthesis of chloride precursor and LW223 from 
3-methyl-4-phenylquinoline-2-carboxylic acid. 
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Supplemental Figure 2. HPLC and MS analysis of LW223 rotamers. A) LCMS trace 
of LW223 showing existence of two rotamers. B) Expansion of LC-MS trace of LW223. 
C) MS of first rotamer (12.493 minutes). D) MS of second rotamer (12.722 minutes). 
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Brain Tissue for 
Binding Assays 
Heart Tissue for 
Binding Assays 
25055 7626 
24781 26124 
24778 20592 
22629 25055 
21396 001.29466 
18391 2580 
9508 26309 
4176 29084 
13410 3784 
2564 4176 
3785 18393 
3783 3786 
2576 18392 
2575 25751 
2572 22611 
2562 9508 
2559 2473 
2558  
2552  
2551  
2550  
2452  
24340  
22630  
22628  
22612  
20593  
20121  
18407  
15809   
Supplemental Table 1. Edinburgh Brain and Tissue Bank BNN reference number 
for all tissues utilized from the bank. 
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Supplemental Figure 3. Representative examples of different models versus 
measured data on naive rat organs. A) Logan modelling in the heart, B) lung and C) 
brain. Modelling constrained to a t*=30min. D) 1T modelling in the heart, E) lung and F) 
brain. G) 2T modelling in the heart, H) lung and I) brain. 
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Region Group 
AIC (Mean± SEM) 
2T 1T Logan 
Heart 
Naive 47.8± 6.3 131.9± 2.7 125.8± 4.4 
MI 52.1± 4.2 135.5± 4.8 132.7± 1.6 
Blocked Naive 132± 27.3 110.2± 31.5 118.1± 6.3 
LV 
Anterior 
Wall 
Naive 127.9± 12.4 159.1± 6.2 144.5± 1.9 
MI 121.5± 8.9 143.7± 7.1 151.7± 2.1 
Blocked Naive 160.7± 15.5 136.6± 3.9 148.6± 5.1 
Brain 
Naive 42.8± 3.4 100.6± 4.8 117.1± 3.1 
MI 57.8± 12.9 118.8± 9.7 118.6± 3.5 
Blocked Naive 153.3± 18 128.9± 4.4 128.3± 5.3 
Lungs 
Naive 62.6± 5.7 105.4± 4.1 112.6± 2.8 
MI 60.7± 4 123.9± 7.8 120.7± 2.6 
Blocked Naive 156.5± 21.4 138.1± 1.8 119.6± 6.5 
  Group Mean 98.0 127.8 128.2 
 
Supplemental Table 2. The Akaike information criterion (AIC) for assessed models 
in all animals and regions used in this study, naive n =  6, MI n =  9, blocked naive 
n =  3. 
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Organ Mouse Human Correction Factor % Total body weight % Total body weight 
Brain 1.62 1.93 1.19 
Heart 0.48 0.43 0.89 
Lung 0.53 1.36 2.55 
Gall Bladder 0.03 0.01 0.44 
Liver 4.00 2.59 0.65 
Gut 5.01 0.92 0.18 
Adrenals 0.02 0.02 1.09 
Kidney 1.28 0.41 0.32 
Bladder 0.08 0.06 0.76 
Supplemental Table 3. Scaling factors for different organs in mice and humans 
based on their percentage contribution to total body weight. Data presented in this 
table was calculated based on previously published data.  
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Supplemental Figure 4. Dissociation constant (Kd) values and maximal binding 
(Bmax) of PK11195 in human brain and heart. A) Kd values of PK11195 and B) Bmax 
calculated from saturation binding assays. Results represent the mean±S.E.M., brain n = 
6, heart n = 5, ns=not significant, *=p<0.05 using an unpaired t-test for brain versus heart. 
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Supplemental Figure 5. Individually calculated Ki values for TSPO ligands using 
human brain and heart. A) PK11195 binding affinities in brain calculated using one-site 
fitting, HAB n = 6, MAB n = 8 and LAB n = 4 and B) heart calculated using a one-site 
fitting, HAB n = 4, MAB n = 5 and LAB n = 4. C) PBR28 binding affinities in brain calculated 
using a one-site fitting apart from MAB where a two-site fitting was used, HAB n = 4, MAB 
n = 5 and LAB n = 4 and D) heart calculated using a one-site fitting, HAB n = 4, MAB n = 
5 and LAB n = 4. E) AB5186 binding affinities in brain calculated using a one-site fitting 
apart from MAB where a two-site fitting was used, HAB n = 6, MAB n = 6 and LAB n = 5 
and F) heart using a one-site fitting apart from MAB where a two-site fitting was used, 
HAB n = 4, MAB n = 5 and LAB n = 4. G) LW223 binding affinities in brain calculated 
using a one-site fitting, HAB n = 5, MAB n = 5 and LAB n = 4 and H) heart calculated 
using a one-site fitting, HAB n = 5, MAB n = 5 and LAB n = 4. ns=not significant, *=p<0.05, 
**=p≤0.01 and ***=p≤0.001 using an unpaired t-test for HAB vs. LAB. All results represent 
the mean±SEM.  
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Supplemental Figure 6. Representative chromatograms of arterial blood sampled 
at 2-120 min post-injection of 18F-LW223. A) Radiodetection of parent peak and 
radiometabolites in rat atrial plasma at 2 min, B) 5 min, C) 10 min, D) 20 min, E) 30 min, 
F) 60 min and G) 120 min post intravenous bolus administration of 18F-LW223. 
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Supplemental Figure 7. Representative chromatograms of organs sampled at 60 
and 120 min post-injection of 18F-LW223. A) Radiodetection of parent peak and 
radiometabolites in rat heart at 60 min, B) heart at 120 min post injection, C) lung at 60 
min, D) lung at 120 min, E) brain at 60 min and F) brain at 120 min post intravenous bolus 
administration of 18F-LW223. 
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Supplemental Figure 8. SUV time activity curves in naive and naive blocking 
studies. A) The effect of PK11195 blockade (1 mg/kg) on 18F-LW223 in the heart, B) 
lung, C) brain and D) sampled left ventricle (LV) anterior wall. Mean ±SEM, naive n = 6, 
blocked n = 3. E) Example time activity curves from a single naive and F) blocked naive 
animal demonstrating the noise which is present in the LV subregion sample. 
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Supplemental Figure 9. In vivo displacement of 18F-LW223 using PK11195 in naive 
rats. A) SUV sum image of 18F-LW223 uptake before and after B) displacement with 
PK11195 (1mg/kg). Top row=brain, middle row=heart and bottom row=lung. Baseline 
images are averaged before (45-60 min) and displacement images are averaged after 
(95-120 min) PK11195 administration. C) Time activity curve of 18F-LW223 before and 
after (green arrow) PK11195 challenge. 
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Region Group 
K1 k2 k3 k4 k3/k4 VT 
Mean± 
S.E.M. 
% SE± 
S.E.M 
Mean± 
S.E.M. 
% SE± 
S.E.M 
Mean± 
S.E.M. 
% SE± 
S.E.M 
Mean± 
S.E.M. 
% SE± 
S.E.M 
Mean± 
S.E.M. 
% SE± 
S.E.M 
Mean± 
S.E.M. 
% SE± 
S.E.M 
Global 
Heart 
Naive 0.58± 0.06 
6.09± 
0.99 
0.33± 
0.01 
12.24± 
1.51 
0.031± 
0.004 
18.51± 
2.04 
0.01± 
0.00 
46.319± 
9.764 
4.77± 
0.27 32.43± 7.72 
9.93± 
0.98 
29.09± 
6.83 
MI 0.58± 0.04 
6.57± 
0.71 
0.36± 
0.03 
13.46± 
1.07 
0.04± 
0.004 
17.38± 
1.46 
0.01± 
0.00 
38.834± 
5.141 
6.62± 
0.98 26.94± 4.09 
12.57± 
1.39 
25.22± 
4.06 
Blocked 
Naive 
0.19± 
0.01 
68.38± 
50.01 
0.23± 
0.02 
464.35± 
402.47 
0.721± 
0.638 
66.85± 
24.71 
0.13± 
0.11 
475.458± 
399.637 
4.52± 
0.66 
472.01± 
411.64 
4.56± 
0.22 
23.00± 
13.02 
LV 
Anterior 
Wall 
Naive 0.9± 0.11 
15.67± 
1.03 
0.26± 
0.03 
36.50± 
3.72 
0.033± 
0.005 
59.73± 
13.92 
0.00± 
0.00 
224.581± 
74.786 
7.99± 
1.21 
176.71± 
61.63 
29.95± 
3 
164.47± 
53.64 
MI 0.25± 0.03 
13.95± 
1.42 
0.18± 
0.02 
36.24± 
3.63 
0.025± 
0.003 
71.52± 
12.28 
0.01± 
0.00 
267.21± 
58.427 
7.92± 
1.31 
216.05± 
57.91 
13.62± 
3.21 
201.04± 
55.93 
Blocked 
Naive 
0.28± 
0.01 
115.97± 
106.93 
0.08± 
0.03 
1463.29± 
1425.50 
0.855± 
0.854 
542.66± 
354.24 
0.23± 
0.23 
105717.505± 
102167.414 
12.64± 
8.90 
105197.46± 
101812.77 
75.25± 
63.13 
98934.28± 
98923.61 
Brain 
Naive 0.14± 0.02 
3.82± 
0.21 
0.18± 
0.02 9.89± 0.58 
0.016± 
0.001 
31.48± 
2.63 
0.01± 
0.00 41.74± 3.31 
1.22± 
0.10 20.4± 2.51 
1.6± 
0.17 
12.69± 
2.08 
MI 0.17± 0.01 
5.12± 
0.69 
0.19± 
0.01 
13.53± 
1.84 
0.023± 
0.003 
36.80± 
6.29 
0.02± 
0.00 50.061± 13.8 
1.42± 
0.08 26.99± 7.8 
2.21± 
0.24 
17.20± 
5.84 
Blocked 
Naive 
0.06± 
0 
471.22± 
154.47 
0.11± 
0.02 
18048.79± 
12808.17 
2.324± 
1.818 
15742.04± 
3854.98 
2.33± 
1.03 
20944.155± 
15962.239 
0.71± 
0.32 
36685.81± 
19130.43 
0.93± 
0.02 
21.85± 
4.74 
Lung 
Naive 0.94± 0.06 
6.51± 
0.78 
0.32± 
0.02 
13.99± 
1.06 
0.031± 
0.007 
32.87± 
3.51 
0.02± 
0.00 
38.458± 
7.495 
1.38± 
0.13 20.15± 2.97 
6.94± 
0.51 
10.89± 
2.35 
MI 1.08± 0.17 
7.24± 
0.8 
0.39± 
0.07 
15.09± 
1.01 
0.046± 
0.011 
24.35± 
2.09 
0.02± 
0.00 26.524± 3 
2.49± 
0.34 15.17± 1.02 
10.43± 
1.60 9.36± 0.93 
Blocked 
Naive 
0.16± 
0.04 
19± 
5.43 
0.35± 
0.16 
82.05± 
23.02 
0.181± 
0.119 
132.22± 
30.37 
0.05± 
0.03 
102.311± 
49.984 
3.19± 
0.41 
98.05± 
26.56 
2.2± 
0.19 
37.68± 
22.85 
 Supplemental Table 4. Kinetic modelling data for 2T analysis of 18F-LW223 uptake in naive, myocardial infarction 
(MI) and blocked rats (post injection of PK11195, 1mg/kg). Naive n = 6, MI n = 5, Blocked n = 3. 
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Supplemental Figure 10. Correlation of VT and SUV in naive and MI animals. A) 
Global heart, left ventricle sample, brain and lung correlation in naive rats and B) MI rats. 
C) Global heart and left ventricle sample correlation in naive rats and D) MI rats. Naive n 
= 6, MI n = 9, *=p<0.05, **=p<0.01 and ****=p<0.0001 using Pearson correlation. 
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Supplemental Figure 11. Invasive input function measurements in naive and MI rats 
during 18F-LW223 PET. A) Average time activity curve of whole blood modelled and 
normalized to injection dose. B) Area under the curve for each individual blood curve 
normalized to injection dose. Naive n = 6, MI n = 9, mean ±SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
by on October 12, 2020. For personal use only. jnm.snmjournals.org Downloaded from 
28 
 
 
 
 
 
Supplemental Figure 12. Ex-vivo immunofluorescent staining within the posterior 
left ventricle. A) TSPO expression sampled within the posterior wall of the left ventricle 
in naive and MI hearts. B) CD68 expression sampled within the posterior wall of the left 
ventricle in naive and MI hearts. Results represent the mean±S.E.M., naive n = 3, MI n = 
5. 
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Supplemental Figure 13. 18F-LW223 Autoradiography. A) Example TSPO 
immunofluorescent staining in naive and B) MI hearts. C) Example autoradiography 
image of the same naive and D) MI heart. E) Quantification of the autoradiography in the 
global heart and left ventricle (LV) anterior wall. Results represent the mean±S.E.M., 
naive n = 3, MI n = 5.
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Supplemental Figure 14. Simulation on the effect of changes in K1 on BPND. Example 
of simulated curves with lowest K1=0.01 mL/mim/cc and 4 different BPND values (1= BPND 
of 4; 2= BPND of 10; 3= BPND of 16; and 4= BPND of 20). All simulated curves are noise 
free.  
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Curve K1 simulated 
k2 
simulated 
k3 
simulated 
k4 
simulated BPND simulated 
1 0.9 0.3 0.02 0.005 4 
2 0.9 0.3 0.05 0.005 10 
3 0.9 0.3 0.08 0.005 16 
4 0.9 0.3 0.1 0.005 20 
5 0.7 0.3 0.02 0.005 4 
6 0.7 0.3 0.05 0.005 10 
7 0.7 0.3 0.08 0.005 16 
8 0.7 0.3 0.1 0.005 20 
9 0.5 0.3 0.02 0.005 4 
10 0.5 0.3 0.05 0.005 10 
11 0.5 0.3 0.08 0.005 16 
12 0.5 0.3 0.1 0.005 20 
13 0.3 0.3 0.02 0.005 4 
14 0.3 0.3 0.05 0.005 10 
15 0.3 0.3 0.08 0.005 16 
16 0.3 0.3 0.1 0.005 20 
17 0.1 0.3 0.02 0.005 4 
18 0.1 0.3 0.05 0.005 10 
19 0.1 0.3 0.08 0.005 16 
20 0.1 0.3 0.1 0.005 20 
21 0.01 0.3 0.02 0.005 4 
22 0.01 0.3 0.05 0.005 10 
23 0.01 0.3 0.08 0.005 16 
24 0.01 0.3 0.1 0.005 20 
 
Supplemental Table 5. Kinetic parameters used in simulations. The blood volume 
(vB) was kept at 5% or 0.05 for all simulations. These parameters were based on the 
results of the modelling presented in the paper. 
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urve K1 estimated 
K1 
%SD 
k2 
estimated 
k3 
estimated 
k4 
estimated 
BPND 
estimated 
BPND 
%SD 
BPND simulated – 
BPND estimated 
BPND % 
difference 
BPTC 
estimated 
Weighted 
sum of 
squares 
2TCM 
AIC 
1 0.844 0.367 0.276 0.019 0.005 4.106 4.689 -0.106 -2.648 4.865 58.295 24.853 
2 0.841 0.416 0.271 0.048 0.005 9.839 2.044 0.161 1.611 11.703 55.936 23.242 
3 0.838 0.442 0.266 0.077 0.005 15.422 1.366 0.578 3.613 18.410 55.344 22.827 
4 0.836 0.455 0.263 0.096 0.005 19.004 1.185 0.996 4.980 22.737 55.372 22.847 
5 0.656 0.396 0.275 0.019 0.005 4.127 4.397 -0.127 -3.183 6.289 36.972 7.094 
6 0.654 0.428 0.270 0.048 0.005 9.844 1.931 0.156 1.560 15.061 35.091 5.058 
7 0.651 0.415 0.265 0.077 0.005 15.374 1.413 0.626 3.913 23.612 34.263 4.126 
8 0.650 0.462 0.262 0.096 0.005 18.957 1.212 1.043 5.215 29.187 34.019 3.848 
9 0.467 0.429 0.274 0.019 0.005 4.131 5.080 -0.131 -3.270 8.851 20.523 -15.860 
10 0.465 0.387 0.269 0.048 0.005 9.832 1.802 0.168 1.680 21.153 19.270 -18.320 
11 0.463 0.497 0.263 0.077 0.005 15.347 1.490 0.653 4.081 33.154 18.721 -19.450 
12 0.462 0.282 0.260 0.096 0.005 18.900 1.313 1.100 5.500 40.936 18.504 -19.900 
13 0.279 0.467 0.271 0.019 0.005 4.163 6.155 -0.163 -4.062 14.946 9.359 -46.490 
14 0.277 0.469 0.266 0.048 0.005 9.824 2.093 0.176 1.758 35.441 8.706 -49.310 
15 0.276 0.507 0.260 0.076 0.005 15.284 1.480 0.716 4.475 55.397 8.418 -50.620 
16 0.275 0.472 0.256 0.095 0.005 18.802 1.310 1.198 5.990 68.321 8.280 -51.260 
17 0.090 0.664 0.260 0.018 0.004 4.354 12.591 -0.354 -8.838 48.158 3.830 -81.330 
18 0.090 0.891 0.252 0.046 0.005 9.818 4.715 0.182 1.824 109.327 3.573 -84.040 
19 0.089 0.897 0.244 0.074 0.005 15.011 3.165 0.989 6.181 168.285 3.281 -87.370 
20 0.089 0.901 0.238 0.092 0.005 18.292 2.703 1.708 8.540 205.991 3.183 -88.550 
21 0.007 7.955 0.161 2.000 3008.983 50.000 43.722 -46.000 -1150.000 7616.842 7.101 -57.250 
22 0.006 6.791 0.137 0.033 0.003 10.833 164.239 -0.833 -8.330 1682.012 3.120 -89.330 
23 0.006 6.191 0.116 0.050 0.004 12.443 113.252 3.557 22.231 1961.937 3.070 -89.960 
24 0.006 6.417 0.103 0.059 0.004 13.208 91.255 6.792 33.960 2100.108 3.043 -90.300 
Supplemental Table 6. Estimated kinetic parameters from simulations. Curve numbers related to curve simulated 
kinetic parameters in Supplemental Table 5. K1 is relatively well estimated, however the BPND becomes unstable at low 
levels of K1.
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Time (min) Activity (kBq/cc) 
0.08 20.06 
0.25 127.34 
0.42 237.26 
0.58 356.85 
0.75 387.21 
0.92 345.15 
1.08 298.41 
1.25 253.76 
1.42 211.44 
1.58 187.91 
1.75 175.63 
1.92 160.92 
2.08 158.90 
2.25 153.93 
2.42 154.93 
2.58 149.61 
2.75 140.65 
2.92 131.96 
3.25 133.83 
3.75 129.21 
4.50 125.97 
6.00 120.01 
8.00 110.94 
11.50 99.15 
16.50 89.07 
21.50 78.29 
26.50 70.74 
31.50 66.03 
36.50 61.30 
41.50 56.47 
46.50 53.55 
51.50 49.17 
56.50 46.83 
64.00 42.98 
74.00 37.98 
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84.00 36.45 
94.00 33.08 
104.00 33.56 
114.00 30.45 
Supplemental Table 7. Input function data used for simulation work. 
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Time (min) Parent fraction 
2 0.95 
5 0.82 
10 0.81 
20 0.81 
30 0.77 
60 0.54 
120 0.69 
Supplemental Table 8. Radiometabolite data used for simulation work. 
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Supplemental Figure 15. Quantification of TSPO and CD68 immunofluorescent 
staining. A) TSPO signal within the brain and selected sub-regions of naive and MI rats. 
B) CD68 signal within the brain and selected sub-regions of naive and MI rats. Results 
represent the mean±S.E.M., naive n = 3, MI n = 5. 
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